BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ghoreschi K, Balato A, Enerbäck C, Sabat R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet 2021;397:754-66. [PMID: 33515492 DOI: 10.1016/S0140-6736(21)00184-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 48] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Xiong D, Shi X, Han M, Zhang X, Wu N, Sheng X, Wang J. The regulatory mechanism and potential application of IL-23 in autoimmune diseases. Front Pharmacol 2022;13:982238. [DOI: 10.3389/fphar.2022.982238] [Reference Citation Analysis]
2 Shinno-Hashimoto H, Eguchi A, Sakamoto A, Wan X, Hashimoto Y, Fujita Y, Mori C, Hatano M, Matsue H, Hashimoto K. Effects of splenectomy on skin inflammation and psoriasis-like phenotype of imiquimod-treated mice. Sci Rep 2022;12:14738. [PMID: 36042262 DOI: 10.1038/s41598-022-18900-7] [Reference Citation Analysis]
3 Xi L, Han Y, Liu C, Liu Y, Wang Z, Wang R, Zheng Y. Sonodynamic therapy by phase-transition nanodroplets for reducing epidermal hyperplasia in psoriasis. J Control Release 2022:S0168-3659(22)00545-4. [PMID: 36030991 DOI: 10.1016/j.jconrel.2022.08.038] [Reference Citation Analysis]
4 Kokolakis G, Kreis G, Falqués M, Aparici M, Sondermann W. High Tolerability, Favorable Safety, and Subjects' Preference for a Single 200 mg/2 mL Tildrakizumab Injection: A Phase I, Open-Label, Randomized Crossover Trial in Healthy Volunteers. Dermatol Ther (Heidelb) 2022. [PMID: 35984626 DOI: 10.1007/s13555-022-00789-9] [Reference Citation Analysis]
5 Yu Q, Ge X, Jing M, Mi X, Guo J, Xiao M, Lei Q, Chen M, Wang F. A Systematic Review with Meta-Analysis of Comparative Efficacy and Safety of Risankizumab and Ustekinumab for Psoriasis Treatment. Journal of Immunology Research 2022;2022:1-11. [DOI: 10.1155/2022/2802892] [Reference Citation Analysis]
6 Witte K, Sabat R, Witte-Händel E, Ghoreschi K, Wolk K. Phytotherapeuthics Affecting the IL-1/IL-17/G-CSF Axis: A Complementary Treatment Option for Hidradenitis Suppurativa? Int J Mol Sci 2022;23:9057. [PMID: 36012322 DOI: 10.3390/ijms23169057] [Reference Citation Analysis]
7 Pan Y, Du D, Wang L, Wang X, He G, Jiang X. The Role of T Helper 22 Cells in Dermatological Disorders. Front Immunol 2022;13:911546. [DOI: 10.3389/fimmu.2022.911546] [Reference Citation Analysis]
8 Barros G, Duran P, Vera I, Bermúdez V. Exploring the Links between Obesity and Psoriasis: A Comprehensive Review. IJMS 2022;23:7499. [DOI: 10.3390/ijms23147499] [Reference Citation Analysis]
9 Zuo Y, Dai L, Li L, Huang Y, Liu X, Liu X, Duan X, Jiang S, Deng G, Chen H. ANGPTL4 Regulates Psoriasis via Modulating Hyperproliferation and Inflammation of Keratinocytes. Front Pharmacol 2022;13:850967. [DOI: 10.3389/fphar.2022.850967] [Reference Citation Analysis]
10 Ujiie H, Rosmarin D, Schön MP, Ständer S, Boch K, Metz M, Maurer M, Thaci D, Schmidt E, Cole C, Amber KT, Didona D, Hertl M, Recke A, Graßhoff H, Hackel A, Schumann A, Riemekasten G, Bieber K, Sprow G, Dan J, Zillikens D, Sezin T, Christiano AM, Wolk K, Sabat R, Kridin K, Werth VP, Ludwig RJ. Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases. Front Med (Lausanne) 2022;9:875492. [PMID: 35755063 DOI: 10.3389/fmed.2022.875492] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
11 Hildenbrand K, Aschenbrenner I, Franke FC, Devergne O, Feige MJ. Biogenesis and engineering of interleukin 12 family cytokines. Trends Biochem Sci 2022:S0968-0004(22)00138-4. [PMID: 35691784 DOI: 10.1016/j.tibs.2022.05.005] [Reference Citation Analysis]
12 Xiao T, Sun M, Kang J, Zhao C. Transient Receptor Potential Vanilloid1 (TRPV1) Channel Opens Sesame of T Cell Responses and T Cell-Mediated Inflammatory Diseases. Front Immunol 2022;13:870952. [PMID: 35634308 DOI: 10.3389/fimmu.2022.870952] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Reich K, Augustin M, Gerdes S, Ghoreschi K, Kokolakis G, Mößner R, Mrowietz U, Navarini AA, Pinter A, Schäkel K, Staubach P, Sticherling M, Thaçi D, Wilsmann-Theis D. Generalisierte pustulöse Psoriasis: Überblick zum Status quo und Ergebnisse einer Diskussionsrunde. J Dtsch Dermatol Ges 2022;20:753-72. [PMID: 35711041 DOI: 10.1111/ddg.14764_g] [Reference Citation Analysis]
14 Reich K, Augustin M, Gerdes S, Ghoreschi K, Kokolakis G, Mößner R, Mrowietz U, Navarini AA, Pinter A, Schäkel K, Staubach P, Sticherling M, Thaçi D, Wilsmann-Theis D. Generalized pustular psoriasis: overview of the status quo and results of a panel discussion. J Dtsch Dermatol Ges 2022;20:753-71. [PMID: 35674482 DOI: 10.1111/ddg.14764] [Reference Citation Analysis]
15 Zhou Y, Li X, Shen R, Wang X, Zhang F, Liu S, Li D, Liu J, Li P, Yan Y, Dong P, Zhang Z, Wu H, Zhuang L, Chowdhury R, Miller M, Issa M, Mao Y, Chen H, Feng J, Li J, Bai C, He F, Tao W. Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways. Front Immunol 2022;13:884399. [DOI: 10.3389/fimmu.2022.884399] [Reference Citation Analysis]
16 McDonald BD, Dyer EC, Rubin DT. IL-23 Monoclonal Antibodies for IBD: So Many, So Different? J Crohns Colitis 2022;16:ii42-53. [PMID: 35553664 DOI: 10.1093/ecco-jcc/jjac038] [Reference Citation Analysis]
17 Xie W, Xiao S, Huang H, Zhang Z. Incidence of and Risk Factors for Paradoxical Psoriasis or Psoriasiform Lesions in Inflammatory Bowel Disease Patients Receiving Anti-TNF Therapy: Systematic Review With Meta-Analysis. Front Immunol 2022;13:847160. [PMID: 35300336 DOI: 10.3389/fimmu.2022.847160] [Reference Citation Analysis]
18 Su S, Katopodi X, Pita-juarez YH, Maverakis E, Vlachos IS, Adamopoulos IE. Serine and arginine rich splicing factor 1 deficiency alters pathways involved in IL-17A expression and is implicated in human psoriasis. Clinical Immunology 2022. [DOI: 10.1016/j.clim.2022.109041] [Reference Citation Analysis]
19 Tan HB, Zheng YQ, Zhuang YP. IL-17A in diabetic kidney disease: protection or damage. Int Immunopharmacol 2022;108:108707. [PMID: 35344813 DOI: 10.1016/j.intimp.2022.108707] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Xu J, Chen H, Chu Z, Li Z, Chen B, Sun J, Lai W, Ma Y, He Y, Qian H, Wang F, Xu Y. A multifunctional composite hydrogel as an intrinsic and extrinsic coregulator for enhanced therapeutic efficacy for psoriasis. J Nanobiotechnology 2022;20:155. [PMID: 35331238 DOI: 10.1186/s12951-022-01368-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
21 Yu Z, Yu Q, Xu H, Dai X, Yu Y, Cui L, Chen Y, Gu J, Zhang X, Guo C, Shi Y. IL-17A promotes Psoriasis-associated Keratinocyte Proliferation via ACT1-depedent Activation of YAP-AREG Axis. J Invest Dermatol 2022:S0022-202X(22)00201-9. [PMID: 35304250 DOI: 10.1016/j.jid.2022.02.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Gómez-garcía F, Gómez-arias PJ, Montilla-lópez A, Hernández-parada J, Sanz-cabanillas JL, Ruano J, Parra-peralbo E. A Scoping Review on Use of Drugs Targeting the JAK/STAT Pathway in Psoriasis. Front Med 2022;9:754116. [DOI: 10.3389/fmed.2022.754116] [Reference Citation Analysis]
23 Tang L, Li T, Zhang B, Zhang Z, Sun X, Zhu Y, Feng B, Su Z, Yang L, Li H, Liu H, Chen Y, Dai Z, Zheng X, Li M, Li C, Zhao J, Qiu X, Ye S, Liu H, Zheng G, Li B, Lu C. Punicalagin Alleviates Psoriasis by Inhibiting NF-κB-Mediated IL-1β Transcription and Caspase-1-Regulated IL-1β Secretion. Front Pharmacol 2022;13:817526. [PMID: 35153790 DOI: 10.3389/fphar.2022.817526] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Guo H, Li M, Liu H. Selenium-Rich Yeast Peptide Fraction Ameliorates Imiquimod-Induced Psoriasis-like Dermatitis in Mice by Inhibiting Inflammation via MAPK and NF-κB Signaling Pathways. Int J Mol Sci 2022;23:2112. [PMID: 35216231 DOI: 10.3390/ijms23042112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Hu P, Wang M, Gao H, Zheng A, Li J, Mu D, Tong J. The Role of Helper T Cells in Psoriasis. Front Immunol 2021;12:788940. [PMID: 34975883 DOI: 10.3389/fimmu.2021.788940] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
26 Rakowsky S, Papamichael K, Cheifetz AS. Choosing the right biologic for complications of inflammatory bowel disease. Expert Review of Gastroenterology & Hepatology. [DOI: 10.1080/17474124.2022.2036122] [Reference Citation Analysis]
27 Ishitsuka Y, Roop DR. The Epidermis: Redox Governor of Health and Diseases. Antioxidants (Basel) 2021;11:47. [PMID: 35052551 DOI: 10.3390/antiox11010047] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
28 Sabnis RW. Novel Difluorocyclohexyl Derivatives as IL-17 Modulators for Treating Inflammatory and Autoimmune Diseases. ACS Med Chem Lett 2021;12:1883-4. [PMID: 34917245 DOI: 10.1021/acsmedchemlett.1c00608] [Reference Citation Analysis]
29 Goh BH, Mocan A, Xiao J, Mah SH, Yap WH. Editorial: Targeting Human Inflammatory Skin Diseases With Natural Products: Exploring Potential Mechanisms and Regulatory Pathways. Front Pharmacol 2021;12:791151. [PMID: 34867426 DOI: 10.3389/fphar.2021.791151] [Reference Citation Analysis]
30 Kokolakis G, Vadstrup K, Hansen JB, Carrascosa JM. Brodalumab Is Associated with High Rates of Complete Clearance and Quality of Life Improvement: A Subgroup Analysis of Patients with Psoriasis and Concomitant Psoriatic Arthritis. Dermatology 2021;:1-10. [PMID: 34823247 DOI: 10.1159/000520290] [Reference Citation Analysis]
31 Ghoreschi K. Targeting Immune Checkpoints and Cytokines to Protect From Psoriasis Relapse. JAMA Dermatol 2021;157:1269-71. [PMID: 34643654 DOI: 10.1001/jamadermatol.2021.3491] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Kokolakis G, Sabat R, Fischer I, Gomis-Kleindienst S, Fritz B, Burmester GR, Ghoreschi K, Ohrndorf S. The Effect of TNF-α Inhibitors on Nail Psoriasis and Psoriatic Arthritis-Real-World Data from Dermatology Practice. J Pers Med 2021;11:1083. [PMID: 34834435 DOI: 10.3390/jpm11111083] [Reference Citation Analysis]
33 Caseley EA, Lara-Reyna S, Poulter JA, Topping J, Carter C, Nadat F, Spickett GP, Savic S, McDermott MF. An Atypical Autoinflammatory Disease Due to an LRR Domain NLRP3 Mutation Enhancing Binding to NEK7. J Clin Immunol 2021. [PMID: 34671876 DOI: 10.1007/s10875-021-01161-w] [Reference Citation Analysis]
34 Ghoreschi K, Augustin M, Baraliakos X, Krönke G, Schneider M, Schreiber S, Schulze-Koops H, Zeißig S, Thaçi D. TYK2-Inhibition: Potenzial bei der Behandlung chronisch-entzündlicher Immunerkrankungen. J Dtsch Dermatol Ges 2021;19:1409-20. [PMID: 34661350 DOI: 10.1111/ddg.14585_g] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Sabnis RW. Imidazo[1,2-b]pyridazines as IL-17A Inhibitors for Treating Psoriasis, Rheumatoid Arthritis, and Multiple Sclerosis. ACS Med Chem Lett 2021;12:1526-7. [PMID: 34676030 DOI: 10.1021/acsmedchemlett.1c00470] [Reference Citation Analysis]
36 Han MM, Yuan XR, Shi X, Zhu XY, Su Y, Xiong DK, Zhang XM, Zhou H, Wang JN. The Pathological Mechanism and Potential Application of IL-38 in Autoimmune Diseases. Front Pharmacol 2021;12:732790. [PMID: 34539413 DOI: 10.3389/fphar.2021.732790] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
37 Fragoulis GE, Brock J, Basu N, McInnes IB, Siebert S. The role for JAK inhibitors in the treatment of immune-mediated rheumatic and related conditions. J Allergy Clin Immunol 2021;148:941-52. [PMID: 34450118 DOI: 10.1016/j.jaci.2021.08.010] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Kluwig D, Huth S, Abdallah AT, Pfaff CM, Fietkau K, Huth L, Marquardt Y, Baron JM, Lüscher B. Establishment of an Intradermal Ear Injection Model of IL-17A and IL-36γ as a Tool to Investigate the Psoriatic Cytokine Network. Life (Basel) 2021;11:846. [PMID: 34440590 DOI: 10.3390/life11080846] [Reference Citation Analysis]
39 Xu Y, Zhu J, Hu J, Zou Z, Zhao Y, Lai L, Xu P, Song Y, Cheng H. L-Theanine Alleviates IMQ-Induced Psoriasis Like Skin Inflammation by Downregulating the Production of IL-23 and Chemokines. Front Pharmacol 2021;12:719842. [PMID: 34381369 DOI: 10.3389/fphar.2021.719842] [Reference Citation Analysis]
40 Bellinato F, Gisondi P, Girolomoni G. Latest Advances for the Treatment of Chronic Plaque Psoriasis with Biologics and Oral Small Molecules. Biologics 2021;15:247-53. [PMID: 34239295 DOI: 10.2147/BTT.S290309] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
41 Ben Abdallah H, Johansen C, Iversen L. Key Signaling Pathways in Psoriasis: Recent Insights from Antipsoriatic Therapeutics. Psoriasis (Auckl) 2021;11:83-97. [PMID: 34235053 DOI: 10.2147/PTT.S294173] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
42 Solimani F, Meier K, Ghoreschi K. Janus kinase signaling as risk factor and therapeutic target for severe SARS-CoV-2 infection. Eur J Immunol 2021;51:1071-5. [PMID: 33675065 DOI: 10.1002/eji.202149173] [Cited by in Crossref: 5] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]